News Trump signs order to hasten psychedelic medicine access Donald Trump has signed an executive order directing the FDA to reduce regulatory hurdles that stand in the way of bringing psychedelics to patients.
R&D 3 big unanswered questions about psychedelics When it comes to psychedelics in the mental health space, there are still some important foundational questions lacking settled answers.
Patients Exploring mixed episodes in bipolar I disorder: When mania a... One of the most misunderstood and often overlooked aspects of BD-I is the occurrence of mixed episodes.
Patients World Bipolar Day: Recognising bipolar I disorder and addres... BD-I is a brain-based condition that affects mood and energy regulation to an extent that disrupts daily life.
R&D Ending trial-and-error: How psychedelics and precision medic... The next phase of psychiatry must go toward treatments that are not only novel, but practical, personalised, and accessible.
News Precision psychiatry push starts in Europe As geopolitical tensions ratchet up around the world, an initiative has been launched to drive improvements in diagnostic accuracy and precision care.
News Chiesi signs $1.9bn deal to buy KalVista and its HAE drug Chiesi has boosted its rare disease business with an agreement to buy KalVista and Ekterly, its oral drug for treating attacks in rare disease HAE.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.